Logo

OKYO

OKYO Pharma Limited

OKYO

OKYO Pharma Limited • NASDAQ
$1.96 ▲ 0.51% (+0.01)
Market Cap $73.72 M
52w High $3.35
52w Low $0.90
Dividend Yield 0%
P/E -16.33
Volume 62.52K
Outstanding Shares 37.61M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $0 $7.185M ▲ $-2.026M ▲ 0% $-0.04 ▲ $-7.082M ▼
Q2-2025 $0 $1.107K ▼ $-2.68M ▼ 0% $-0.08 ▲ $-1.669K ▲
Q4-2024 $0 $3.642K ▼ $-8.008K ▲ 0% $-0.24 ▼ $-7.012K ▲
Q2-2024 $0 $4.6K ▲ $-8.817K ▼ 0% $-0 $-8.733K ▼
Q4-2023 $0 $3.756K $-7.783K 0% $-0 $-7.696K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $1.561M ▲ $3.677M ▲ $9.227M ▼ $-5.55M ▲
Q2-2025 $987.199K ▲ $2.829M ▲ $10.054M ▲ $-7.226M ▼
Q4-2024 $826.848K ▼ $1.541M ▲ $7.421M ▲ $-5.88M ▼
Q2-2024 $4.045M $0 ▼ $2.053M ▼ $-2.053M
Q4-2023 $4.045M $5.204M $7.257M $-2.053M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-2.027M ▼ $-1.57M ▼ $-1.208K ▼ $2.105M ▲ $573.703K ▲ $-1.572M ▼
Q2-2025 $-2.678K ▲ $-241.455K ▼ $0 $552.084K ▲ $279.884K ▲ $-241.46K ▼
Q4-2024 $-8.008K ▲ $-2.696K ▲ $0 $2.208K ▼ $-1.617K ▲ $-2.696K ▲
Q2-2024 $-8.817K ▼ $-6.793K ▼ $0 ▲ $4K ▼ $-4.045K ▼ $-6.793K ▼
Q4-2023 $-7.783K $-4.197K $-2.992 $7.535K $1.529K $-4.2K

Five-Year Company Overview

Income Statement

Income Statement OKYO is still a pure research-stage biotech, so it has essentially no product revenue yet. The income statement is dominated by R&D and operating costs, which lead to ongoing net losses. These losses appear relatively small in absolute terms but are persistent, which is typical for an early-stage biotech that has not yet commercialized a drug. Earnings per share bounce around partly because the base is small and funding rounds or share changes can move the figures noticeably. Overall, the business is in the classic pre-revenue phase: expenses for science and clinical trials, no offsetting sales yet.

Balance Sheet

Balance Sheet The balance sheet looks very light, reflecting a small company with limited assets and no debt on the books. Cash levels and total assets are modest, suggesting a constrained financial base. Equity recently dipped into negative territory, which indicates accumulated losses have outpaced the capital raised so far. That combination—thin assets, no debt, and negative equity—underscores that OKYO is financially lean and heavily dependent on continued external funding rather than internally generated capital or a large asset cushion.

Cash Flow

Cash Flow Cash flows are driven almost entirely by operating needs for R&D and general expenses, with no meaningful investment spending on physical assets and no cash inflows from product sales. Operating and free cash flow have been mildly but consistently negative, which is expected for a clinical-stage biotech without revenue. This means the company’s ability to keep funding trials depends on raising capital through equity or partnerships. There is no sign yet of self-funding from operations; cash burn management and access to new financing remain critical watch points.

Competitive Edge

Competitive Edge Competitively, OKYO occupies a focused niche in eye diseases, particularly inflammatory conditions and ocular pain. Its lead candidate, urcosimod, is differentiated by trying to tackle both inflammation and pain at once, rather than just one of these, which could offer a clinical edge if trial results continue to be favorable. The company also benefits from a first-mover position in neuropathic corneal pain, an area with no approved treatments, and has supportive elements like FDA Fast Track status and growing patent protection in the U.S. and Europe. On the other hand, OKYO is small and going up against large, well-funded ophthalmology and biotech players, while still needing to prove its efficacy and safety in larger, later-stage trials. Its competitive position is therefore promising but still unproven and highly dependent on clinical outcomes.

Innovation and R&D

Innovation and R&D Innovation is the core of OKYO’s story. Urcosimod uses a novel mechanism that targets specific receptors involved in both inflammation and pain, and its lipid-anchor design is meant to keep the drug on the eye surface longer, potentially improving effectiveness. The company is also leveraging this technology across multiple potential indications—dry eye disease, neuropathic corneal pain, and other inflammatory eye conditions—giving it a chance to extend the value of a single platform. Fast Track designation and patent wins strengthen the R&D narrative, while a second early-stage, non-opioid pain candidate (OK-201) shows attempts to broaden the pipeline. The main risk is concentration: much of the future hinges on one lead program succeeding in rigorous clinical trials, with timing and regulatory outcomes still uncertain.

Summary

OKYO Pharma is an early-stage biotech focused on novel treatments for eye inflammation and ocular pain, operating without product revenue and funding its work through external capital while incurring ongoing research-driven losses. Its financial structure is light and high-risk, with limited assets, negative equity, and continuing cash burn, leaving it sensitive to financing conditions. Strategically, the company’s value proposition rests on differentiated science in urcosimod, a potential first-in-class drug in neuropathic corneal pain and a dual-action approach for dry eye and related conditions, backed by growing patent protection and regulatory support. The upside case centers on successful clinical and regulatory milestones over the next few years, while the key risks include clinical failure, delays, funding constraints, and intense competition from larger ophthalmology and biotech companies. Overall, OKYO is best viewed as a high-risk, innovation-driven platform still in the proof-of-concept phase, with outcomes heavily dependent on the progress of its lead programs.

NEWS

November 21, 2025 · 8:30 AM UTC

OKYO Pharma Announces Chairman and Founder Acquires Shares

Read more

November 18, 2025 · 8:30 AM UTC

OKYO Pharma to Present at OIS XV in San Diego

Read more

October 16, 2025 · 8:30 AM UTC

OKYO Pharma Announces Chairman and Founder Acquires Shares

Read more

September 22, 2025 · 8:30 AM UTC

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Read more